Although selective serotonin reuptake inhibitors (SSRIs) are reported to be effective in decreasing posttraumatic stress disorder (PTSD) symptoms, a subgroup of PTSD patients remain chronically symptomatic and maintain conditioned fear responses to traumatic stimuli. In this context, the establishment of an appropriate animal model of PTSD is necessary to promote better understanding of the mechanisms of the disorder and to facilitate the development of more effective therapeutic alternatives to SSRIs. Although no single widely accepted animal model of PTSD has been established to date, the single prolonged stress (SPS) animal model has been partially validated as a model for PTSD. SPS rats mimic the pathophysiological abnormalities and behavioral characteristics of PTSD, such as enhanced anxiety-like behavior and glucocorticoid negative feedback, and they exhibit the expected therapeutic response to paroxetine on enhanced fear memory. In addition, SPS rats exhibit enhanced freezing in response to contextual fear conditioning, and impaired extinction of fear memory, which is alleviated by D-cycloserine. The enhanced consolidation and impaired extinction of fear memory found in SPS rats suggests that this model has additional value because recent studies of PTSD indicate that memory abnormalities are a central feature. In this study, we summarize the behavioral and pathophysiological PTSD-like symptoms in SPS, focusing on memory abnormalities, and evaluate the validity of SPS as an animal model of PTSD. Depression and Anxiety 26:1110–1117, 2009.

© 2009 Wiley-Liss, Inc.

Key words: posttraumatic stress disorder; single prolonged stress; animal model; contextual fear; fear extinction

INTRODUCTION

Posttraumatic stress disorder (PTSD) develops following exposure to life-threatening trauma, and according to the DSM-IV diagnostic criteria, involves characteristic features such as persistent experiencing of trauma, avoidance, numbing, and hyperarousal. Although many individuals with PTSD recover during the first couple of years following traumatic exposure, up to 30–40% remain chronically symptomatic. Furthermore, individuals with chronic PTSD were shown to maintain conditioned fear responses to traumatic stimuli.

Published online 16 November 2009 in Wiley InterScience (www.interscience.wiley.com).
even 40–50 years after the trauma.[3] Thus, the high prevalence, chronicity, and resistance to treatment underscore the importance of the development of effective therapeutic strategies for PTSD. In this context, the establishment of an appropriate animal model of PTSD can promote our understanding of the mechanisms of PTSD and may help to identify novel and more effective therapeutic strategies.

Ultimately, the optimal animal model would mimic the pathophysiological abnormalities and behavioral characteristics of PTSD and involve exposure to trauma-like events. No single widely accepted animal model of PTSD has been established to date and there is an ongoing debate over what constitutes a valid animal model for this disorder. Among various animal models of PTSD proposed, a single prolonged stress (SPS) model, proposed by Liberzon et al., replicates the specific neuroendocrinological abnormalities observed in PTSD patients[20,21] such as enhanced glucocorticoid negative feedback. According to their method, SPS is conducted in three stages. Briefly, animals are restrained for 2 hr and immediately afterwards undergo a 20 min forced swim in 24°C water. The forced swim is performed with six rats at a time in an 18 gallon plastic tub (55.6 cm diameter, 45.4 cm height) two-thirds full. Following recuperation for 15 min, animals are exposed to ether until the loss of consciousness and then left undisturbed in their home cage for 7 days. Consistent with time-dependent sensitization (TDS) studies,[6] it was proposed that the undisturbed period is a necessary condition to produce PTSD-like manifestations. As a result, behavioral experiments are generally undertaken 7–14 days after the SPS procedure. SPS is not the only animal model of PTSD that has been proposed, and various animal paradigms have been developed in an attempt to model the disorder. These include exposure to various stressors such as electric shock,[7–11] underwater trauma,[12] and exposure to predators[13,14] or predator-related cues.[12,15,16] Exposure to these stressors leads to an increase in anxiety-like behaviors, and in some cases, exaggerated startle responses, cognitive impairment, enhanced fear conditioning, and reduced social interaction.[17] Some studies have also reported physiological changes (e.g. hypothalamic–pituitary–adrenal (HPA) axis) resembling those observed in patients with PTSD.[17,18] Studies using inescapable shock (IS) in a shuttle-box are of particular interest. Rats exposed to IS exhibit PTSD-like bidirectional behavioral changes; that is, “avoidance/numbing” (e.g. decreased activity, reactivity, and interest in surroundings) and “hyperarousal” (e.g. irritability and exaggerated responsiveness to external stimuli) in an avoidance/escape task session (2 weeks after IS).[17,19]

Each of these animal models has some degree of face and construct validity for PTSD; however, it is beyond the scope of the present work to provide a detailed comparison of these animal models. In this article, we describe the PTSD-like behavioral and pathophysiological symptoms of SPS and discuss the validity of SPS as an animal model of PTSD.

PTSD-LIKE SYMPTOMS IN SPS

HYPOTHALAMO–PITUITARY–ADRENAL (HPA) AXIS

The biological basis of PTSD is still largely unknown. However, various HPA axis abnormalities have been repeatedly reported in PTSD, including low levels of cortisol in urine and plasma, enhanced suppression of cortisol in response to administration of low-dose dexamethasone (a synthetic corticosteroid), and glucocorticoid receptor abnormalities.[20,21] Exaggerated suppression of plasma cortisol in response to low-dose dexamethasone appears to be the most commonly reported finding.[22] Yehuda et al. examined the levels of cortisol and the number of lymphocyte glucocorticoid receptors before and after administration of 0.5 or 0.25 mg dexamethasone in 14 combat veterans with PTSD, 12 combat veterans without PTSD, and 14 nonpsychiatric healthy men. At both doses of dexamethasone, combat veterans with PTSD showed greater suppression of cortisol as compared with combat veterans without PTSD and normal controls.[23] These clinical findings suggest that an appropriate animal model of PTSD would exhibit enhanced negative feedback of the HPA axis after exposure to synthetic glucocorticoids.

Liberzon et al. originally developed the SPS model and found that it was associated with enhanced negative feedback of the HPA axis, as indicated by plasma ACTH levels after cortisol administration.[4] Furthermore, to determine the neural mechanisms of enhanced negative feedback of the HPA axis, Liberzon et al. also examined regional changes in Type I (MR) and Type II (GR) glucocorticoid receptor mRNA distribution in the hippocampus using in situ hybridization.[5] Five group of rats were studied: control group, SPS–7 days group (no sensitization period), SPS group, SPS+7 days group (14 days sensitization), and SPS+chronic stress group (chronic stress during 7 days sensitization). The SPS+chronic stress group was exposed to four different stressors on a variable schedule for 7 days. Twenty-four hours after SPS, down-regulation of GR and MR mRNA was found across all hippocampal subfields. Seven days later (full SPS group), there was a differential recovery, with GR mRNA reaching higher than the prestress levels and MR mRNA remaining downregulated. The same differential regulation was present in the SPS+7 days group. The SPS+chronic stress group, which exhibited normally fast feedback, also showed normalization of GR and MR mRNA levels. It was concluded that a sensitization period of 7 days was necessary (SPS–7, and SPS+chronic stress controls), which led to persistent changes (SPS+7 days) in the glucocorticoid receptor ratio in hippocampus. As hippocampal glucocorticoid receptors play a central role in glucocorticoid negative feedback regulation,[24] these findings suggest that the increase in GR in the hippocampus is involved in the fast feedback hypersensitivity observed in SPS rats.

Depression and Anxiety
GLUTAMATE AND GABA

Although HPA abnormalities are probably the most specific neurobiological findings associated with PTSD, the complex symptoms associated with the disease suggest involvement of other neurotransmitters and various circuits governing cognitive and emotional processing. Reliable animal models provide the opportunity to examine these candidate systems such as the major excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitter systems. Dysfunction in brain glutamatergic systems, involving N-methyl-D-aspartate (NMDA) receptors in particular, has been suggested as a neurobiological component of PTSD, perhaps contributing to hippocampal toxicity. Harvey et al. demonstrated in a radioligand binding assay that NMDA receptor density was reduced in the rat hippocampus after SPS. In concert with the change in NMDA receptor density, spatial memory deficits in the Morris water maze were exhibited. As NMDA pathways in the hippocampus are crucial for memory function, the reduction in NMDA receptor density in this study may underlie the cognitive changes observed in the SPS model. We also have observed NMDA changes in SPS rats, such as significant upregulation of hippocampal NMDA receptor subunit mRNAs 7 days after SPS. Although the reported changes in receptor density and subunit mRNA appear to occur in opposition to one another, the precise mechanism by which receptor density and subunit changes translate into functional deficits remain unknown; it would therefore be premature to consider them contradictory. It is also plausible that the difference in experimental procedures (e.g., modified SPS vs. SPS, duration after exposure to SPS) contributed to this discrepancy. Together these findings suggest, however, that glutamatergic-NMDA systems might be altered in SPS animals.

GABA(A) receptors are thought to play an important role in modulating the central nervous system in response to stress. Geuze et al. reported differences in the benzodiazepine-GABA(A) receptor complex in PTSD using [(11)C]-flumazenil and positron emission tomography. PTSD veterans showed significantly reduced [(11)C]-flumazenil binding throughout the cortex, hippocampus, and thalamus. Harvey et al. reported reduced hippocampal GABA levels, as measured by high-performance liquid chromatography, in a rat model of SPS. Furthermore, Khan and Liberzon demonstrated that topiramate (which has GABA(A)-modulating properties) attenuated the enhanced acoustic startle response in SPS rats. Together, these findings support the hypothesis that hypofunction of the GABAergic pathway could be, at least in part, involved in the pathophysiology of PTSD.

FEAR RESPONSE

Trauma-related and -unrelated fear response. In addition to their value for studying neurotransmitters, animal models are useful for examining specific brain circuitry that might be involved in PTSD pathophysiology. In this respect, SPS animals have been used to examine fear response circuitry implicated in PTSD, since some PTSD symptoms, like exaggerated reaction to trauma-related events and re-experiencing, suggest that fear learning or fear conditioning are involved. Patients with PTSD also demonstrate hyperarousal and hypervigilance responses to more general aversive (trauma-unrelated) stimuli. Enhanced autonomic arousal responses, such as increased skin conductance, have been reported in PTSD, and are induced by stressors unrelated to trauma. Orr et al. reported larger heart rate responses to sudden, loud tones (trauma-unrelated) in Vietnam combat veterans with PTSD.

Similarly, a number of animal studies have reported that SPS rats exhibit enhanced trauma-unrelated fear. In these studies, rats were first subjected to SPS and then exposed to contextual fear conditioning, where fear-inducing stimuli and the context are not associated with initial trauma (SPS). In a study by Takahashi et al., the contextual fear paradigm was performed after a 14-day undisturbed period following SPS. On the first day of fear conditioning, rats were exposed to the context (180 s, in the conditioning chamber (325 W x 280 H x 500 D mm) without any stimulation). Immediately after that, they were administered a foot shock (0.8 mA, 4 s). Twenty-four hours later, the rats were placed back in the conditioning chamber where the foot shock was delivered, and the duration of freezing was evaluated. SPS rats showed a significant increase in contextual freezing as compared with rats not subjected to SPS.

In addition, as a method of evaluating the non-associative fear response, symptoms of hypervigilance and hyperarousal can be assessed by measuring increases in the amplitude of startle responses to tones or airpuffs of defined intensity. In a study by Khan and Liberzon, SPS rats were found to exhibit increased startle responses to 50 ms and 108 dB tones, both when compared with a nonstressed control group or with their own startle responses before the SPS session.

To our knowledge, no studies reported in the literature have examined fear responses to trauma-related stimuli using the SPS paradigm. We, therefore, examined behavioral activity in response to the forced swimming test (FST) to evaluate trauma-related fear in SPS rats. The experimental design is shown in Figure 1. The test was conducted 7 days after the SPS procedure. In the control group, rats first underwent forced swimming for 20 min, instead of the SPS procedure. In both groups, immobility was measured in comparison with the first FST session (for the first 5 min of the 20 min period). The results showed that the duration of immobility during the second FST was significantly longer than that during the first FST in the SPS group (Fig. 2). In contrast, there was no significant difference in immobility between the first and second FST in the sham group (Fig. 2).
These findings should be interpreted discreetly because there is a possibility that increased immobility represents not only the enhanced fear response in PTSD-like symptoms, but also the despair-like response in depression. Therefore, we performed the tail suspension test to differentiate the enhanced fear response from the despair-like response. The test was conducted 7 days after the SPS procedure. Rats were suspended by their tails for 6 min, and the duration of immobility was measured according to the method described by Steru et al. There was no significant difference in immobility between the SPS and sham groups according to unpaired Student's t-test ($t(16) = 0.11, P = 0.91$).

**Fear extinction.** PTSD patients exhibit long-lasting reexperience of traumatic events and avoidance of the trauma-related stimuli, even though they recognize that the traumatic event is no longer occurring. Recent advances in our understanding of the mechanisms underlying fear extinction have led to the hypothesis that dysfunctional fear extinction plays an important role in the development of clinical symptoms, such as reexperiencing of trauma, in PTSD. In fact, a recent study, in which a 2-day fear conditioning and extinction procedure was used, showed that PTSD patients are deficient in extinction recall. On day 1 of the study, subjects viewed colored light-conditioned stimuli, some of which were paired with mild electric shock, followed by extinction of the conditioned responses in another context. On the second day, extinction recall was tested in the previous extinction context. Skin conductance response was the dependent measure. The retention of extinction measured on the second day was deficient in the PTSD combat veterans relative to non-PTSD combat veterans.

In parallel, using animal models, we have recently examined the ability of SPS to impair fear extinction and to test whether D-cycloserine (DCS) can alleviate impaired fear extinction in SPS rats. In that study, contextual fear conditioning was conducted 7 days after the SPS procedure. Twenty-four hours after fear conditioning, rats were placed for 10 min without footshock in the same chamber where the footshock was first delivered. In a similar manner, extinction training was performed on each of 5 consecutive days following fear conditioning. DCS was administered daily for 6 days (from the end of fear conditioning to the beginning of the fifth extinction training session). SPS rats exhibited impaired fear extinction when compared with sham rats, and DCS ameliorated the impairment of fear extinction.

*Depression and Anxiety*
In a human clinical pilot study, Heresco-Levy et al. demonstrated insufficient efficacy of DCS in the treatment of PTSD. In that study, DCS was given chronically without exposure therapy. More recent studies in animals and humans have shown that DCS enhances fear extinction when given in conjunction with extinction training. Therefore, it is important to note that DCS administration has only minimal effect unless it is combined with extinction training. Together, these findings support the notion that impaired extinction is the mechanism responsible for the development of PTSD re-experiencing, and that SPS animals mimic some of the same abnormalities in fear extinction seen in PTSD patients. Additional studies investigating increased resistance to extinction of the conditioned fear response are needed to further elucidate the validity of SPS as an animal model of PTSD.

**OTHER PTSD-LIKE SYMPTOMS**

In addition to exaggerated fear responses, traumatic memories, and avoidance, PTSD has been associated with additional deficits/symptoms. Verbal memory impairments, indicative of hippocampal dysfunction, have been often reported in PTSD. Bremner et al. used a neuropsychological test as a probe of hippocampal function in 26 Vietnam veterans with combat-related PTSD and 15 matched healthy control subjects. Compared with controls, the combat veterans showed a decrease in immediate and delayed recall, as well as in percent retention, in the presence of similar IQ scores. The same group also reported similar results with adult survivors of severe childhood physical or sexual abuse who presented for psychiatric treatment.

Using a modified SPS paradigm, Harvey et al. showed that these rats exhibit spatial memory deficits in the Morris water maze and this finding was confirmed by Kohda et al. However, it is also possible that conditioned fear contributed to these learning deficits, as the original SPS session included a swim period. Richter-Levin evaluated the conditioning effects of an underwater trauma on the Morris water maze performance. Both 1 hr and 3 weeks after the trauma, significant behavioral deficits were observed in the water maze; however, they were context specific. Underwater trauma in a different (out-of-context) water container had no effects on a spatial memory task in the water maze. Based on these findings, the SPS learning deficits in the water maze are not likely to be due to the effects of conditioned fear because the context of the water maze differs from that of the SPS session.

The clinical picture of PTSD often involves social isolation and discomfort in novel environments. These factors may be modeled in animal studies employing exploratory-based approach–avoidance conflict tests, which assess the impact of fear of open and/or brightly lit areas on the exploration of novel environments. Imanaka et al. reported that SPS rats showed a significant decrease in the percentage of open arm entries and the percentage of open arm time in the elevated plus maze test, indicating that SPS induces alterations of anxiety-related behavior.

Finally, two studies examined stress-induced analgesia, which is often seen in PTSD patients and SPS animals. In the model used in these studies, animals are placed individually into the testing chamber and a flinch-jump test is performed while shocks are delivered to the grid floor of the chamber through a shock generator. After a 3-min period of habituation, upwards shock titrations are continued in a stepwise manner (0.05 mA, 0.05–0.8 mA range). The flinch threshold is defined as the lowest shock intensity that elicited any detectable response. The vocalization threshold is defined as the lowest shock intensity that elicited vocalization, and the jump threshold, as the lowest shock intensity that elicited simultaneous removal of at least three paws (including both hindpaws) from the grid. In these studies, shock-induced vocalization and jump thresholds were significantly increased in SPS rats as compared with control animals.

**SPS AS AN ANIMAL MODEL OF PTSD**

The validity of an animal model is typically assessed using three validity criteria: phenomenological similarity (face validity), corresponding theoretical explanatory frameworks (construct validity), and the ability to predict that a pharmacological agent with efficacy demonstrated in animal studies to have a subsequent therapeutic effect in humans (predictive validity). The substantial evidence supporting the face and construct validity of the SPS model suggests that it could be suitable for the study of PTSD; however, there are unresolved issues that require further exploration. Regarding face validity, although there is accumulating evidence that SPS rats exhibit symptoms of increased arousal, such as exaggerated fear responses to trauma-related and -unrelated stimuli, avoidance of stimuli associated with trauma or emotional blunting have not been studied in SPS. With respect to construct validity, several SPS studies suggested hippocampal abnormality, which has also been implicated in patients with PTSD, but other brain areas such as the amygdala or medial prefrontal regions, implicated in PTSD by functional neuroimaging studies, have not been yet been investigated in the SPS model.

Although pharmacotherapy for PTSD is still at a relatively early stage of development, sustained administration of selective serotonin reuptake inhibitors (SSRIs) has proven to be highly effective in decreasing PTSD symptoms. Thus, the appropriate predictive ability can be demonstrated by chronic administration of SSRIs in the SPS model, which would be expected to ameliorate PTSD-like symptoms. In fact, several recent studies have demonstrated the efficacy of SSRIs on PTSD-like symptoms in SPS rats. Takahashi
et al. showed that 14-day oral administration of paroxetine (PRX) immediately after exposure to SPS, at a dose sufficient to produce clinically relevant serum concentrations, was effective in the prevention of enhanced contextual freezing in SPS rats. Interestingly, acute administration of PRX at a dose that resulted in clinically relevant serum concentrations did not affect enhanced freezing. Wang et al. have also demonstrated the efficacy of PRX on PTSD-like symptoms in a modified SPS model. In their study, a single electric footshock was given to rats immediately after administration of SPS (SPS+Shock). PRX administered for 14 days immediately after SPS+Shock prevented the induction of PTSD-like symptoms such as enhanced conditioning fear responses and anxiety behaviors. Taken together, the effect of PRX on PTSD-like symptoms in SPS rats suggests a sufficient degree of predictive validity for this animal model. Further studies are needed to evaluate the efficacy of other types of SSRIs and drugs, such as propranolol, on PTSD-like symptoms in SPS rats.

In addition to the criteria mentioned above, Yehuda and Antelman previously proposed criteria specific for animal models of PTSD. The main aim of the criteria is to define the stressor in detail. As described above, SPS consists of three stresses: 2 hr restraint, forced swim, and ether anesthesia, which correspond to psychological, physiological, and endocrinological stress, respectively. The sequence of stresses in the SPS model is somewhat arbitrary and does not simulate the common set of trauma experienced by patients with PTSD (i.e. lack of ecological validity). However, each of the three stresses markedly increase serum corticosterone levels, and by combining the three different stresses, the SPS model could achieve severity of symptoms similar to that of PTSD. Also, the risk of habituation processes that diminish the effect of the stressor could be avoided. Furthermore, SPS can lead to enhanced negative feedback of the HPA axis 7 days after SPS, through TDS, and this endocrinological characteristic, which has been consistently replicated in the SPS model, is one of the advantages of SPS over other animal models of PTSD.

One of the limitations of the SPS model, according to the criteria by Yehuda and Antelman, is that the intensity of the stressor cannot be modified; the stressor does not produce PTSD-like symptoms in a dose-dependent manner. It is unclear whether or not SPS can induce bi-directional emotional responses; reduced responsiveness to the stressor (avoidance and/or numbing) has not been well studied. Lastly, further studies are needed to determine the degree of inter-individual variability in response to stressors in the SPS model.

CONCLUSIONS

The behavioral and endocrinological responses to stimuli, molecular changes in the hippocampus, and therapeutic response to PRX and DCS observed in SPS rats support the face, construct, and predictive validity of this model as an animal analog of PTSD. The usefulness of this model is further supported by the interesting data generated by additional neurotransmitter studies and specific neurocircuitry studies. Overall, the findings show that the SPS paradigm has been partially validated as an animal model of PTSD. However, additional issues need to be addressed in order to refine and further validate the model; further studies are therefore warranted.

Acknowledgments. This work was supported by a grant-in-aid for general scientific research from the Ministry of Education, Science, and Culture of Japan, a Health Science Research Grant for Research on Brain Science from the Ministry of Health and Welfare of Japan, and a grant from Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology (JST).

REFERENCES


